Cancer Research Targets  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 68, 530, January 15, 2008. doi: 10.1158/0008-5472.CAN-07-5269
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Koshikawa, N.
Right arrow Articles by Seiki, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koshikawa, N.
Right arrow Articles by Seiki, M.

Cell, Tumor, and Stem Cell Biology

Development of a New Tracking Tool for the Human Monomeric Laminin-{gamma}2 Chain In vitro and In vivo

Naohiko Koshikawa1, Tomoko Minegishi1, Kazuki Nabeshima2 and Motoharu Seiki1

1 Division of Cancer Cell Research, Institute of Medical Science, University of Tokyo, Tokyo, Japan and 2 Department of Pathology, Fukuoka University Hospital, Fukuoka, Japan

Requests for reprints: Motoharu Seiki, Division of Cancer Cell Research, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan. Phone: 81-3-5449-5255; Fax: 81-3-5449-5414; E-mail: mseiki{at}ims.u-tokyo.ac.jp.

Laminin-5 (Ln-5), a heterotrimer composed of three different laminin chains [laminin-{alpha}3 (Ln-{alpha}3), laminin-β3 (Ln-β3), and laminin-{gamma}2 (Ln-{gamma}2)], is a major component of the basement membrane in most adult tissues. One of the chains, Ln-{gamma}2, is a specific marker of invasive tumors because it is frequently expressed as a monomer in malignant tumors. However, there is no simple and direct method to detect the monomeric form of Ln-{gamma}2 selectively in the presence of Ln-5 because all available antibodies recognize both monomeric and heterotrimeric forms of Ln-{gamma}2. In this study, we developed a new monoclonal antibody (mAb) termed 1H3 that reacts specifically with human Ln-{gamma}2 monomers during immunoprecipitation, ELISA, Western blotting, and immunostaining. Ln-5 was not recognized by mAb 1H3 after denaturation with detergents under nonreducing conditions, but reactivity was recovered when denaturation was done under reducing conditions. The epitope of the antibody was mapped to region on the coiled-coil structure formed between Ln-{gamma}2 and its partner chains Ln-{alpha}3 and Ln-β3 in Ln-5, whose structure is further stabilized by disulfide bonds. In normal tissue samples, the basement membrane was stained with conventional antibody against Ln-{gamma}2 but not by mAb 1H3. In contrast, tumor cells in tissue sections could be stained with mAb 1H3 as efficiently as with conventional antibody. Thus, mAb 1H3 holds promise as a powerful tracking tool for the specific detection of monomeric Ln-{gamma}2 in vivo and in vitro and is potentially useful as a diagnostic tool for detecting tumors and as a vehicle for drug delivery to cancer tissues. [Cancer Res 2008;68(2):530–6]







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.